WILMINGTON, DE — Incyte (Nasdaq: INCY) will present full results from a Phase 3 study of tafasitamab for first-line diffuse large B-cell lymphoma at the American Society of Clinical Oncology Annual Meeting in Chicago from May 29 through June 2, 2026.
The data come from the frontMIND trial, which evaluated tafasitamab in combination with lenalidomide and R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
The study results will be delivered during an oral abstract session on May 30 focused on hematologic malignancies, including lymphoma and chronic lymphocytic leukemia.
“The positive Phase 3 frontMIND results for tafasitamab…highlight Incyte’s continued focus on advancing…approaches with the potential to…impact patients,” said Pablo J. Cagnoni, president and global head of research and development at Incyte.
Tafasitamab is a monoclonal antibody targeting CD19, designed to induce B-cell destruction through immune-mediated mechanisms.
In the United States, the therapy is approved in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, and has accelerated approval with lenalidomide for certain patients with relapsed or refractory diffuse large B-cell lymphoma.
The drug is also approved in Europe and Japan for specific lymphoma indications, including relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.
Additional details about the ASCO meeting are available at https://www.asco.org/annual-meeting.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.